Aspirin-Sensitive Asthma

  • Andrzej Szczeklik
  • Ewa Nizankowska-Mogilnicka
  • Marek Sanak
Part of the Allergy Frontiers book series (ALLERGY, volume 3)

Most people tolerate aspirin and other nonsteroidal anti-inflammatory drugs (NSAID) well. Asthmatics, however, are exception. First reports on the attacks of bronchoconstriction following aspirin ingestion appeared over a hundred years ago, shortly after introduction of aspirin into therapy. It took several decades to realize that aspirin-induced asthma (AIA), as it started to be addressed, constitutes a clear-cut clinical syndrome. Some of the mechanisms operating in the syndrome have been clarified, but its origin still awaits the explanation. Within the last years a few reviews on AIA were published [1-5]. In this paper we, therefore, concentrate on the most recent findings, following presentation of the basic data.


Allergy Clin Immunol Nasal Polyp Nasal Polyposis Allergy Asthma Immunol Aspirin Desensitization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Szczeklik A, Sanak M (2006) The broken balance in aspirin hypersensitivity. Eur J Pharmacol 533:145–155.PubMedCrossRefGoogle Scholar
  2. 2.
    Stevenson DD, Szczeklik A (2006) Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118:773–786.PubMedCrossRefGoogle Scholar
  3. 3.
    Kowalski M, Makowska JS (2006) Aspirin-exacerbated respiratory disease. An update on diagnosis and management. Allergy Clin Immunol Int – J World Allergy Org 18:140–149.CrossRefGoogle Scholar
  4. 4.
    Szczeklik A, Nizankowska-Mogilnicka E, Sanak M (2007) Hypersensitivity to aspirin and other NSAIDs: mechanisms, clinical presentation and management. In: Pichler WJ (ed) Drug Hypersensitivity. Basel, Switzerland, Karger, pp. 340–351.Google Scholar
  5. 5.
    Wenzel SE (2006) Asthma: defining of the persistent adult phenotypes. Lancet 368:804–813.PubMedCrossRefGoogle Scholar
  6. 6.
    Jenkins C, Costello J, Hodge L (2004) Systematic review of prevalence of aspirin-induced asthma and its implications for clinical practice. BMJ 328:434–437.PubMedCrossRefGoogle Scholar
  7. 7.
    Szczeklik A, Nizankowska Mogilnicka E, Sanak M (2008) Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Adkinson NF, Busse W, Bodnner BS, Holgate ST, Simons FER, Lemanslec RF (eds) Middleton's Allergy: Principles and practice. 7th Ed. Mosby Inc, Elsevier, London, pp.1227–1243.Google Scholar
  8. 8.
    Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ (2005) The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocations challenge study. J Pediatr 147:233–238.PubMedCrossRefGoogle Scholar
  9. 9.
    Szczeklik A, Nizankowska E, Duplaga M (2000) Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur Respir J 16:432–436.Google Scholar
  10. 10.
    Berges-Gimeno M, Simon RA, Stevenson DD (2002) The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474–478.PubMedGoogle Scholar
  11. 11.
    Szczeklik A (1988) Aspirin-induced asthma as a viral disease. Clin Allergy 18:15–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Szczeklik A, Nizankowska E, Mastalerz L, Bochenek G (2002) Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol 109:572–573.PubMedCrossRefGoogle Scholar
  13. 13.
    Koga T, Oshita Y, Kamimura T, Koga H, Aizawa H (2006) Characterisation of patients with frequent exacerbation of asthma. Respir Med 100:273–278.PubMedCrossRefGoogle Scholar
  14. 14.
    Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A, Arakawa M, Yoshizawa H, Gejyo F (2005) Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 10:477–484.PubMedCrossRefGoogle Scholar
  15. 15.
    Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L for the TENOR Study Group (2005) Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116:970–975.PubMedCrossRefGoogle Scholar
  16. 16.
    Bochenek G, Nizankowska E, Szczeklik A (1996) The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 51:16–23.PubMedGoogle Scholar
  17. 17.
    Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G (1975) Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1:67–60.PubMedGoogle Scholar
  18. 18.
    Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G (1977) Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 60:276–284.PubMedCrossRefGoogle Scholar
  19. 19.
    Mathison DA, Stevenson DD (1979) Hypersensitivity to non-steroidal anti-inflammatory drugs: indications and methods for oral challenge. J Allergy Clin Immunol 64:669–674.PubMedCrossRefGoogle Scholar
  20. 20.
    Czerniawska-Mysik G, Szczeklik A (1981) Idiosyncrasy to pyrazolone drugs. Allergy 36:381–384.PubMedCrossRefGoogle Scholar
  21. 21.
    Asero R (2000) Multiple sensitivities to NSAIDs. Allergy 55:893–894.PubMedCrossRefGoogle Scholar
  22. 22.
    Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, D'Ambrosio FP, Venuti A (2000) Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal antiinflammatory drugs. Ann Allergy Asthma Immunol 84:613–617.PubMedGoogle Scholar
  23. 23.
    Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z (2004) Safety of selective COX-2 inhibitors in aspirin/NSAID intolerant patients: comparison of nimesulide, meloxicam and rofecoxib. J Asthma 41:67–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z (2007) Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 142:64–69.CrossRefGoogle Scholar
  25. 25.
    Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H (2000) Selective cyclo-oxygenase 2 inhibitor in pateints with aspirin-induced asthma. J Allergy Clin Immunol 106:1201–1202.PubMedCrossRefGoogle Scholar
  26. 26.
    Stevenson DD, Simon RA (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108:47–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31:219–225.PubMedCrossRefGoogle Scholar
  28. 28.
    Woessner KM, Simon RA, Stevenson DD (2002) The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis and Rheumatism 46:2201–2206.PubMedCrossRefGoogle Scholar
  29. 29.
    Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlén SE, Szczeklik A, Murray JJ, Dahlén B (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase-2 selective analgetic drug celecoxib. J Allergy Clin Immunol 111:1116–1121.PubMedCrossRefGoogle Scholar
  30. 30.
    El Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:105–109.PubMedGoogle Scholar
  31. 31.
    Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A (2006) Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 117:1189–1190.PubMedCrossRefGoogle Scholar
  32. 32.
    Levy MB, Fink JN (2001) Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 87:72–73.PubMedGoogle Scholar
  33. 33.
    Murr D, Bocquet H, Lelouet H, Fischer RM, Revuz J, Cosnes A (2003) Adverse cutaneous reaction to celecoxib: 6 cases. Ann Dermatol Venereol 130:519–521.PubMedGoogle Scholar
  34. 34.
    Passero M (2003) Cyclooxygenase-2 inhibitors in aspirin sensitive asthma. Chest 123:2155–2156.PubMedCrossRefGoogle Scholar
  35. 35.
    Baldassarre S, Schandene L, Choufani G, Michils A (2006) Asthma attacks induced by low doses of celecoxib, aspirin and acetaminophen. J Allergy Clin Immunol 117:215–217.PubMedCrossRefGoogle Scholar
  36. 36.
    Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A (2006) Different eicosanoid profile of the hypersensitivtiy reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma and urticaria. J Allergy Clin Immunol 118:957–958.PubMedCrossRefGoogle Scholar
  37. 37.
    Morais-Almeida M, Marinho S, Rosa S, Gaspar A, Rosado-Pinto JE (2006) Multiple drug intolerance including etoricoxib. Allergy 61:144–145.PubMedCrossRefGoogle Scholar
  38. 38.
    Woś M, Sanak M, Burchell L, Mosser A, Soja J, Olechnowicz H, Szczeklik A, Busse W (2008) Rhinovirus infection in lower airways of asthmatic patients. J Allergy Clin Immunol 117:S314.CrossRefGoogle Scholar
  39. 39.
    Peng T, Kotla S, Bumgarner RE, Gustin KE (2006) Human rhinovirus attenuates the type I interferon response by disrupting activation of interferon regulatory factor 3. J Virol 80:5021–5031.PubMedCrossRefGoogle Scholar
  40. 40.
    Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stnca V, Holgate ST, Davies DE (2005) Asthmatic bronchial epithelial cells have a deficient immune response to infection with rhinovirus. J Exp Med 21:937–947.CrossRefGoogle Scholar
  41. 41.
    Contoli M, Message SD, Laza-Stanc V, Edwards MR, Wark PAB, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL (2006) Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12:1023–1026.PubMedCrossRefGoogle Scholar
  42. 42.
    Dekker JW, Niżankowska E, Schmitz-Schumann M, Pile K, Bochenek G, Dyczek A, Cookson WO, Szczeklik A (1997) Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 27:574–577.PubMedCrossRefGoogle Scholar
  43. 43.
    Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, Park HS (2004) HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol 113:562–564.PubMedCrossRefGoogle Scholar
  44. 44.
    Kim SH, Park HS, Holloway JW, Shin HD, Park CS (2007) Association between a TGFβ1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. Resp Med 101:490–495.CrossRefGoogle Scholar
  45. 45.
    Szczeklik A, Sanak M (2002) The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 32:339–342.PubMedCrossRefGoogle Scholar
  46. 46.
    Picado C, Fernandez-Morata JC, Roc-Ferrer J, Fuentes M, Xaubet A, Mullol J (1999) Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 160:291–296.PubMedGoogle Scholar
  47. 47.
    Kowalski ML, Pawliczak R, Wozniak J, Sluda M, Poniatowska J, Iwaszkiewicz T, et al. (2000) Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 161:391–398.PubMedGoogle Scholar
  48. 48.
    Pierzchalska M, Szabo Z, Sanak M, Soja J, Szczeklik A (2003) Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 111:1041–1048.PubMedCrossRefGoogle Scholar
  49. 49.
    Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L (2003) Differential effects of aspirin and misoprostol on 15-hydroxyecosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 112:505–512.PubMedCrossRefGoogle Scholar
  50. 50.
    Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Grzegorczyk J, Pawliczak R, DuBuske L (2005) Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 60:1139–1145.PubMedCrossRefGoogle Scholar
  51. 51.
    Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH (2006) Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 117:312–318.PubMedCrossRefGoogle Scholar
  52. 52.
    Celik G, Bavbek S, Misirligi Z, Melli M (2001) Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 31:1615–1622.PubMedCrossRefGoogle Scholar
  53. 53.
    Jinnai M, Sakagani T, Sekigawa T, Kakihara M, Nakajima T, Yoshud K, Goto S, Hasegawa T, Koshino T, Hasegawa Y, Inoue H, Suzuki N, Sano Y, Inoue I (2004) Polymorphisms in the prostaglandin E2 receptor subtype 2 confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 13:3203–3217.PubMedCrossRefGoogle Scholar
  54. 54.
    Sladek K, Szczekilk A (1993) Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 6:39–399.Google Scholar
  55. 55.
    Sladek K, Dworski R, Soja J, Sheller JR, Niżankowska E, Oates JA, Szczeklik A (1994) Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 149:940–946.PubMedGoogle Scholar
  56. 56.
    Sanak M, Sampson AP (1999) Biosynthesis of cysteinyl leucotrienes in aspirin-intolerant asthma. Clin Exp All 29:306–316.CrossRefGoogle Scholar
  57. 57.
    Antczak A, Montuschi P, Kharitonov S, Górski P, Barnes PJ (2002) Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002 166:301–306.CrossRefGoogle Scholar
  58. 58.
    Obase Y, Shimoda T, Tomari SY, Mitsuta K, Kawano T, Matsuse H, Kohno S (2002) Effects of pranlukast on chemical mediators in induce sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 121:143–150.PubMedCrossRefGoogle Scholar
  59. 59.
    Świerczyńska M, Niżankowska-Mogilnicka E, Zarychta J, Gielicz A, Szczeklik A (2003) Nasal versus bronchial and nasal response to oral aspirin challenge: clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol 112:995–1001.PubMedCrossRefGoogle Scholar
  60. 60.
    Mita H, Turikisawa N, Yamada T, Taniguchi M (2007) Quantification of leukotriene B4 glucuronide in human urine. Prostagland Lipid Mediat 83:42–49.CrossRefGoogle Scholar
  61. 61.
    Cowburn AS, Sladek K, Soja J, Adamek L, Niżankowska E, Szczeklik A, Lam BK, Penrose JF, Austen FK, Holgate ST, Sampson AP (1998) Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin intolerant asthma. J Clin Invest 101:834–846.PubMedCrossRefGoogle Scholar
  62. 62.
    Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A (2000a) Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 23:290–296.Google Scholar
  63. 63.
    Kim SH, Bae JS, Suh CH, Nahm DH, Holloway JW, Park HS (2005a, 2005b) Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 60:760–765.CrossRefGoogle Scholar
  64. 64.
    Kim SH, Choi JH, Park HS, Holloway JW, Lee SK, Shin HD (2005b) Association of thromboxane A2 receptor gene polymorphism with phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 35:585–590.CrossRefGoogle Scholar
  65. 65.
    Kim SH, Oh JM, Kim YS, Palmer LJ, Suh CH, Nahm DH, Park HS (2006) Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 36:433–439.PubMedCrossRefGoogle Scholar
  66. 66.
    Park JS, Chang HS, Park CS, Lee YM, Choi JH, Park HS, Kim LH, Park BL, Choi YH, Shin HD (2005) Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphism with aspirin-intolerant asthma. Pharmacogenet Genomics 20:232–236.Google Scholar
  67. 67.
    Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M, Akiyama K (2001) Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 56:106–1067.Google Scholar
  68. 68.
    Bochenek G, Nagraba K, Niżankowska E, Szczeklik A (2003) A controlled study of 9alpha,11betaPGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 111:743–749.PubMedCrossRefGoogle Scholar
  69. 69.
    Sanak M, Kielbasa B, Bochenek G, Szczeklik A (2004) Exhaled eicosanoids following oral aspirin challege in asthmatic patients. Clin Exp Allergy 34:1899–1904.PubMedCrossRefGoogle Scholar
  70. 70.
    Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishi T, Higashi A, Osame M, Akiyama K (2004) Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113:277–283.PubMedCrossRefGoogle Scholar
  71. 71.
    Sousa AR, Parikhs A, Scadding G, Corrigan CJ, Lee TH (2002) Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347:1493–1499.PubMedCrossRefGoogle Scholar
  72. 72.
    Corrigan C, Mallet K, Ying S, Roberts D, Parikh A, Scadding G, Lee T (2005) Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 115:316–322.PubMedCrossRefGoogle Scholar
  73. 73.
    Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A (2000b) Apirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16:44–49.CrossRefGoogle Scholar
  74. 74.
    Perez-Novo CA, Watelet JB, Clayes C, Van Cauvenberge P, Bachert C (2005) Prostaglandin, leukotriene and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 115:1189–1196.PubMedCrossRefGoogle Scholar
  75. 75.
    Levy BD, Bonnns C, Silverman ES, Palmer LJ, Marigowda G, Israel E (2005) Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 172:824–830.PubMedCrossRefGoogle Scholar
  76. 76.
    Choi JH, Park HS, Oh HB, Lee JH, Suh YJ, Park CS, Shin HD (2004) Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygene. Hum Genet 114:337–344.PubMedCrossRefGoogle Scholar
  77. 77.
    Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Ćmiel A, Gielicz A, Szczeklik A (2008) Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 63:27–34.PubMedCrossRefGoogle Scholar
  78. 78.
    Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antépara I, Esparza R, de Weck AL (2004) The flow-cytometric determination of basophil activation by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 34:1448–1457.PubMedCrossRefGoogle Scholar
  79. 79.
    Dahlen B, Zetterstrom O (1990) Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 3:527–534.PubMedGoogle Scholar
  80. 80.
    Milewski M, Mastalerz L, Nizankowska E, Szczeklik A (1998) Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 101:581–586.PubMedCrossRefGoogle Scholar
  81. 81.
    Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A (2000) Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 15:863–869.PubMedCrossRefGoogle Scholar
  82. 82.
    Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M (2002) Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma. Allergy 57:632–635.PubMedCrossRefGoogle Scholar
  83. 83.
    Stevenson DD, Simon RR, Zuraw BL (2003) Sensitivity to aspirin and NSAIDs. In: Adkinson NJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simon FE (eds) Allergy Principles and Practice, 6th edn. CV Mosby, Middleton, Philadelphia, PA, pp. 1695–1710.Google Scholar
  84. 84.
    Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K (2004) Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy 34:1262–1269.PubMedCrossRefGoogle Scholar
  85. 85.
    Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A (2007) EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62(10):1111–1118.PubMedCrossRefGoogle Scholar
  86. 86.
    Williams AN, Simon RA, Woessner KM, Stevenson DD (2007) The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 120(2):273–277.PubMedCrossRefGoogle Scholar
  87. 87.
    White AA, Bigby T, Stevenson DD (2006) Intranasal ketorolac challenge for the diagnosis of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:190–195.PubMedGoogle Scholar
  88. 88.
    Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K (2004) Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy 34:1262–1269.PubMedCrossRefGoogle Scholar
  89. 89.
    Nizankowska E, Duplaga M, Bochenek G, Szczeklik A on behalf of the AIANE project (1998) Clinical course of aspirin-induced asthma, results of AIANE. In: Szczeklik A, Gryglewski R, Vane J (eds) Eicosanoids, Aspirin and Asthma. Marcel Dekker, New York, pp. 451–472.Google Scholar
  90. 90.
    Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE (1998) Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187–1194.PubMedGoogle Scholar
  91. 91.
    Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW (2004) Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 59:289–294.PubMedCrossRefGoogle Scholar
  92. 92.
    Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, Sayers I (2000) Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(Suppl):S28–S31.PubMedCrossRefGoogle Scholar
  93. 93.
    Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, Hakuno H, Fukunaga K, Suzuki Y, Kanazawa M, Yamaguchi K (2002) Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to an LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12:565–570.PubMedCrossRefGoogle Scholar
  94. 94.
    Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, Bestynska-Krypel A, Cmiel A, Szczeklik A (2002) Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 32:949–955.PubMedCrossRefGoogle Scholar
  95. 95.
    Park HE, Kim SH, Sampson AP, Lee KW, Park CS (2004) The HLA-DPB1&0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma. J Allergy Clin Immunol 114:688–689.PubMedCrossRefGoogle Scholar
  96. 96.
    Aukema AA, Mulder PG, Fokkens WJ (2005) Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. JACI 115:1017–1023.Google Scholar
  97. 97.
    Jankowski R, Pigret D, Decroocq F (1997) Comparison of functional results after ethmoidectomy and nasalization for diffuse and severe nasal polyposis. Acta Otolaryngol (Stockh) 117:601–608.CrossRefGoogle Scholar
  98. 98.
    Hosemann W (2000) Surgical treatment of nasal polyposis in patients with aspirin intolerance. Thorax 55:87–90.CrossRefGoogle Scholar
  99. 99.
    Loehrl TA, Ferre RM, Toohill RJ, Smith TL (2006) Long-term asthma outcomes after endoscopic sinus surgery in aspirin triad patients. Am J Otolaryngol 27:154–160.PubMedCrossRefGoogle Scholar
  100. 100.
    Ragab S, Scadding GK, Lund VJ, Saleh H (2006) Treatment of chronic rhinosinusitis and its effects on asthma. Eur Respir J 28:68–74.PubMedCrossRefGoogle Scholar
  101. 101.
    Stevenson DD (2003) Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 24:159–168.PubMedCrossRefGoogle Scholar
  102. 102.
    Stevenson DD, Simon RA (2006) Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 118:801–804.PubMedCrossRefGoogle Scholar
  103. 103.
    Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA (2004) Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292:3017–3023.PubMedCrossRefGoogle Scholar
  104. 104.
    Silberman S, Neukirch-Stoop C, Steg PG (2005) Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 95:509–510.PubMedCrossRefGoogle Scholar
  105. 105.
    Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, Simon RA, Wald J, Woessner KM; Aspirin Desensitization Joint Task Force (2007) Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 98:172–174.PubMedCrossRefGoogle Scholar
  106. 106.
    Pfaar O, Klimek L (2006) Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol 6:161–166.PubMedGoogle Scholar
  107. 107.
    Lee JY, Simon RA, Stevenson DD (2007) Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 119:157–164.PubMedCrossRefGoogle Scholar
  108. 108.
    Page NA, Schroeder WS (2007) Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Ann Pharmacother 41:61–67.PubMedGoogle Scholar
  109. 109.
    Parikh AA, Scadding GK (2005) Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 115:1385–1390.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Andrzej Szczeklik
    • 1
  • Ewa Nizankowska-Mogilnicka
    • 1
  • Marek Sanak
    • 1
  1. 1.Department of MedicineJagiellonian University School of MedicineCracowPoland

Personalised recommendations